Irish Biotech Opsona Adds Two New Corporate VCs In $43M Series C
This article was originally published in The Pink Sheet Daily
Executive Summary
Irish biotech Opsona Therapeutics recently raised $43 million with the help of four corporate VCs, for use in developing its potential first-in-class product for preventing delayed graft function in high-risk renal transplant patients.
You may also be interested in...
Germany’s Immatics Biotech Raises $46M In Series D To Complete Cancer Vaccine Development
With one of the largest VC-funded financings in Europe this year, the German biotech receives sufficient funds to allow it to prepare marketing submissions for its lead renal cancer vaccine.
Medtech in Ireland -- Turning Green into Gold
Despite the recent downturn in the national economy, Ireland's medical device community is on the verge of a major growth spurt. A lot of the credit goes to strong government support, particularly in the form of Enterprise Ireland, which serves as a major investor in medtech start-ups. Even with such support, Ireland's medtech start-up community faces many of the challenges that any start-up community faces. But the sector has high hopes and great ambitions. The second of a two-part series.
Pipeline Watch: Phase III Readouts in Wilson Disease, Parkinson's Disease And COVID-19
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.